I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| neuron | 6 studies | 34% ± 13% | |
| GABAergic neuron | 5 studies | 35% ± 9% | |
| glutamatergic neuron | 4 studies | 37% ± 14% | |
| interneuron | 4 studies | 25% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| neuron | 6 studies | 34% ± 13% | |
| GABAergic neuron | 5 studies | 35% ± 9% | |
| glutamatergic neuron | 4 studies | 37% ± 14% | |
| interneuron | 4 studies | 25% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 27% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 94% | 2623.99 | 2491 / 2642 | 99% | 42.18 | 697 / 705 |
| prostate | 75% | 773.82 | 184 / 245 | 81% | 13.61 | 406 / 502 |
| ovary | 78% | 432.30 | 141 / 180 | 44% | 4.24 | 190 / 430 |
| uterus | 72% | 419.64 | 122 / 170 | 28% | 4.80 | 128 / 459 |
| bladder | 71% | 964.67 | 15 / 21 | 23% | 2.81 | 117 / 504 |
| intestine | 77% | 2410.16 | 741 / 966 | 14% | 0.96 | 72 / 527 |
| blood vessel | 88% | 881.81 | 1174 / 1335 | 0% | 0 | 0 / 0 |
| esophagus | 68% | 1078.03 | 987 / 1445 | 14% | 1.02 | 26 / 183 |
| adrenal gland | 8% | 36.82 | 20 / 258 | 74% | 46.79 | 171 / 230 |
| stomach | 36% | 475.13 | 130 / 359 | 19% | 1.46 | 54 / 286 |
| lung | 20% | 75.94 | 116 / 578 | 22% | 2.44 | 252 / 1155 |
| adipose | 25% | 159.51 | 303 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 0% | 0 | 0 / 328 | 18% | 1.51 | 32 / 178 |
| breast | 5% | 28.37 | 25 / 459 | 9% | 0.65 | 96 / 1118 |
| tonsil | 0% | 0 | 0 / 0 | 13% | 2.62 | 6 / 45 |
| thymus | 4% | 21.03 | 29 / 653 | 6% | 0.27 | 34 / 605 |
| kidney | 1% | 3.00 | 1 / 89 | 8% | 0.79 | 71 / 901 |
| skin | 5% | 20.48 | 85 / 1809 | 1% | 0.12 | 7 / 472 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.25 | 1 / 80 |
| liver | 0% | 0 | 0 / 226 | 1% | 0.11 | 4 / 406 |
| spleen | 1% | 2.64 | 2 / 241 | 0% | 0 | 0 / 0 |
| muscle | 0% | 1.49 | 3 / 803 | 0% | 0 | 0 / 0 |
| heart | 0% | 0.67 | 2 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000010 | Biological process | positive regulation of protein localization to cell surface |
| GO_0051131 | Biological process | chaperone-mediated protein complex assembly |
| GO_0005778 | Cellular component | peroxisomal membrane |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0031410 | Cellular component | cytoplasmic vesicle |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0030548 | Molecular function | acetylcholine receptor regulator activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TMEM35A |
| Protein name | Novel acetylcholine receptor chaperone |
| Synonyms | TMEM35 NACHO |
| Description | FUNCTION: Molecular chaperone which mediates the proper assembly and functional expression of the nicotinic acetylcholine receptors (nAChRs) throughout the brain . Essential for the proper folding, assembly, function and surface trafficking of alpha-7 (CHRNA7), alpha-4-beta-2, alpha-3-beta-2 and alpha-3-beta-4 receptors . Stably associates with ribophorin-1 (RPN1) and ribophorin-2 (RPN2) (components of the oligosaccharyl transferase (OST) complex) and with calnexin (CANX), both of which are critical for NACHO-mediated effects on CHRNA7 assembly and function (By similarity). Facilitates the proper folding and assembly of alpha-6-beta-2 and alpha-6-beta-2-beta-3 receptors and acts at early stages of the nAChRs subunit assembly . Promotes the expression of the alpha-4(2):beta-2(3) stoichiometric form over the alpha-4(3):beta-2(2) form . . |
| Accessions | Q53FP2 ENST00000372930.5 |
